nascobal (r) (b 12) demand is strong

Quote






Yes indeed and the canadians seem overmatched on this one.


Now how many analysts have significant first to file sales from tramadol in their late 2009 early 2010 models for PAR?


I am way ahead of the curve as usual on this one!

and did you realize they ie dr damon smith are seeking additional indications for branded tramadol formulations


and there is more much more good news PENDING




(((((((((((((((((( THINK $20 +++ ))))))))))))))))))))
 






Interesting that j&j which sells biovail's version and biovail both withdrew from the lawsuit. While j&j does over $$200m in annual sales , canada's labopharm sells $$$15m and is leading the charge in the delaware court. Talk about poor management when the Canadians continue a costly and designed to fail lawsuit for a $15m market while j&j does over $200m and walks away from the court case with their canadian partner biovail. My bet is on a positive and unexpected surprise for par.



Please keep other news under embargo in the interim.

(((((((((((((((($20))))))))))))))))))))
 












THE P COMPANIES said:
Yes indeed and the canadians seem overmatched on this one.


Now how many analysts have significant first to file sales from tramadol in their late 2009 early 2010 models for PAR?


I am way ahead of the curve as usual on this one!

and did you realize they ie dr damon smith are seeking additional indications for branded tramadol formulations


and there is more much more good news PENDING




(((((((((((((((((( THINK $20 +++ ))))))))))))))))))))
Click to expand...


when can we expect more news?
 




































nascobal sales are even exceeding my estimates

latest sales data indicates weekly scripts at over 900 vs 600 in early april

and this is just as the sales push was beginning

A WHOPPING 50% INCREASE IN SALES BEFORE THE SALES AND MARKETING INITIATIVE

and remember they did a 25% price increase


(((((((((((((((((((((((HUGE)))))))))))))))



((((((((((((($20+++))))))))))))
 






Of the 11 posts on this page, 8 came from P companies as himself, and the other 3 are from P companies pretending to be someone else.

Dude - no one is listening to you any more. This is my first visit to the cafe in over a month and I am shocked you are up the the same shennaningans you were doing 2 years ago. Except back then it was <<<<<Ranbaxy buyout imminent!! Buying with both fists!!! $45/share by year end (07?, 08?, 09?)>>>>>>

You're a joke.
 






Your jealous streak will get you nowhere. A poll of the 75k views disclosed no one wants you here hogster. Your worthless posts are a unnecessary distraction. Stay away dempsey


No one can dispute the IMS data and the initial success of nascobal. NO ONE



((((((((((((((((((((($20 on the way)))))))))))))))))))))))))))
 






Very aggressive call buying yesterday which is very BULLISH going forward. They were buying the 17.50 and 20 calls as they expect par to trade higher much higher very soon.
Much speculation of a buyout is gaining traction all over.
 












Par Pharmaceutical Cos. (PRX US) rose the most since October 2005, jumping $2.44, or 13 percent, to $21.78. The generic-drug maker is a takeover target and two companies in India are among the potential buyers, the Times of India reported from New Delhi, citing sources it didn't identify. Par might sell for as much as $40 a share, Buckingham Research Group analyst David Buck wrote in a research note.
 






Anonymous said:
Par Pharmaceutical Cos. (PRX US) rose the most since October 2005, jumping $2.44, or 13 percent, to $21.78. The generic-drug maker is a takeover target and two companies in India are among the potential buyers, the Times of India reported from New Delhi, citing sources it didn't identify. Par might sell for as much as $40 a share, Buckingham Research Group analyst David Buck wrote in a research note.
Click to expand...


your news is almost 2 years old
this was from september 2007
there is no takeover
you are just trying to get rumors started
 






Who needs rumours?


We have strong nascobal sales, toprol sales are thru the roof, tramadol got ta'd, and blowout earnings are coming

We will run the share price up to where it belongs and then the buyout

Look at noven!
 












With the strong nascobal sales and multiple launches in 2010 for loramyc, odansetron and now tramadol, these shares should hit over $30 in next 9-12 months so your guarantee is plausible.
 






Top Bottom
Back
Quote